Cargando…

Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning

PURPOSE: Carbon ion radiotherapy for prostate cancer was performed using two fine needle Gold Anchor (GA) markers for patient position verification in Osaka Heavy Ion Medical Accelerator in Kansai (Osaka HIMAK). The present study examined treatment plans for prostate cases using beam‐specific planni...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsubouchi, Toshiro, Hamatani, Noriaki, Takashina, Masaaki, Wakisaka, Yushi, Ogawa, Atsuhiro, Yagi, Masashi, Terasawa, Ayumi, Shimazaki, Kazuyuki, Chatani, Masashi, Mizoe, Jun’etsu, Kanai, Tatsuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425940/
https://www.ncbi.nlm.nih.gov/pubmed/34339590
http://dx.doi.org/10.1002/acm2.13376
_version_ 1783749944553766912
author Tsubouchi, Toshiro
Hamatani, Noriaki
Takashina, Masaaki
Wakisaka, Yushi
Ogawa, Atsuhiro
Yagi, Masashi
Terasawa, Ayumi
Shimazaki, Kazuyuki
Chatani, Masashi
Mizoe, Jun’etsu
Kanai, Tatsuaki
author_facet Tsubouchi, Toshiro
Hamatani, Noriaki
Takashina, Masaaki
Wakisaka, Yushi
Ogawa, Atsuhiro
Yagi, Masashi
Terasawa, Ayumi
Shimazaki, Kazuyuki
Chatani, Masashi
Mizoe, Jun’etsu
Kanai, Tatsuaki
author_sort Tsubouchi, Toshiro
collection PubMed
description PURPOSE: Carbon ion radiotherapy for prostate cancer was performed using two fine needle Gold Anchor (GA) markers for patient position verification in Osaka Heavy Ion Medical Accelerator in Kansai (Osaka HIMAK). The present study examined treatment plans for prostate cases using beam‐specific planning target volume (bsPTV) based on the effect of the markers on dose distribution and analysis of target movements. MATERIALS AND METHODS: Gafchromic EBT3 film was used to measure dose perturbations caused by markers. First, the relationships between the irradiated film density and absolute dose with different linear energy transfer distributions within a spread‐out Bragg peak (SOBP) were confirmed. Then, to derive the effect of markers, two types of markers, including GA, were placed at the proximal, center, and distal depths within the same SOBP, and dose distributions behind the markers were measured using the films. The amount of internal motion of prostate was derived from irradiation results and analyzed to determine the margins of the bsPTV. RESULTS: The linearity of the film densities against absolute doses was constant within the SOBP and the amount of dose perturbations caused by the markers was quantitatively estimated from the film densities. The dose perturbation close behind the markers was smallest (<10% among depths within the SOBP regardless of types of markers) and increased with depth. The effect of two types of GAs on dose distributions was small and could be ignored in the treatment planning. Based on the analysis results of internal motions of prostate, required margins of the bsPTV were found to be 8, 7, and 7 mm in left–right (LR), anterior–posterior (AP), and superior–inferior (SI) directions, respectively. CONCLUSION: We evaluated the dose reductions caused by markers and determined the margins of the bsPTV, which was applied to the treatment using fiducial markers, using the analysis results of prostate movements.
format Online
Article
Text
id pubmed-8425940
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84259402021-09-13 Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning Tsubouchi, Toshiro Hamatani, Noriaki Takashina, Masaaki Wakisaka, Yushi Ogawa, Atsuhiro Yagi, Masashi Terasawa, Ayumi Shimazaki, Kazuyuki Chatani, Masashi Mizoe, Jun’etsu Kanai, Tatsuaki J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: Carbon ion radiotherapy for prostate cancer was performed using two fine needle Gold Anchor (GA) markers for patient position verification in Osaka Heavy Ion Medical Accelerator in Kansai (Osaka HIMAK). The present study examined treatment plans for prostate cases using beam‐specific planning target volume (bsPTV) based on the effect of the markers on dose distribution and analysis of target movements. MATERIALS AND METHODS: Gafchromic EBT3 film was used to measure dose perturbations caused by markers. First, the relationships between the irradiated film density and absolute dose with different linear energy transfer distributions within a spread‐out Bragg peak (SOBP) were confirmed. Then, to derive the effect of markers, two types of markers, including GA, were placed at the proximal, center, and distal depths within the same SOBP, and dose distributions behind the markers were measured using the films. The amount of internal motion of prostate was derived from irradiation results and analyzed to determine the margins of the bsPTV. RESULTS: The linearity of the film densities against absolute doses was constant within the SOBP and the amount of dose perturbations caused by the markers was quantitatively estimated from the film densities. The dose perturbation close behind the markers was smallest (<10% among depths within the SOBP regardless of types of markers) and increased with depth. The effect of two types of GAs on dose distributions was small and could be ignored in the treatment planning. Based on the analysis results of internal motions of prostate, required margins of the bsPTV were found to be 8, 7, and 7 mm in left–right (LR), anterior–posterior (AP), and superior–inferior (SI) directions, respectively. CONCLUSION: We evaluated the dose reductions caused by markers and determined the margins of the bsPTV, which was applied to the treatment using fiducial markers, using the analysis results of prostate movements. John Wiley and Sons Inc. 2021-08-02 /pmc/articles/PMC8425940/ /pubmed/34339590 http://dx.doi.org/10.1002/acm2.13376 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Tsubouchi, Toshiro
Hamatani, Noriaki
Takashina, Masaaki
Wakisaka, Yushi
Ogawa, Atsuhiro
Yagi, Masashi
Terasawa, Ayumi
Shimazaki, Kazuyuki
Chatani, Masashi
Mizoe, Jun’etsu
Kanai, Tatsuaki
Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning
title Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning
title_full Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning
title_fullStr Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning
title_full_unstemmed Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning
title_short Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning
title_sort carbon ion radiotherapy using fiducial markers for prostate cancer in osaka himak: treatment planning
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425940/
https://www.ncbi.nlm.nih.gov/pubmed/34339590
http://dx.doi.org/10.1002/acm2.13376
work_keys_str_mv AT tsubouchitoshiro carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT hamataninoriaki carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT takashinamasaaki carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT wakisakayushi carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT ogawaatsuhiro carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT yagimasashi carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT terasawaayumi carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT shimazakikazuyuki carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT chatanimasashi carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT mizoejunetsu carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning
AT kanaitatsuaki carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning